» Articles » PMID: 25644821

Angiotensin-converting Enzyme 2/angiotensin-(1-7)/Mas Axis Prevents Lipopolysaccharide-induced Apoptosis of Pulmonary Microvascular Endothelial Cells by Inhibiting JNK/NF-κB Pathways

Overview
Journal Sci Rep
Specialty Science
Date 2015 Feb 4
PMID 25644821
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

ACE2 and Ang-(1-7) have important roles in preventing acute lung injury. However, it is not clear whether upregulation of the ACE2/Ang-(1-7)/Mas axis prevents LPS-induced injury in pulmonary microvascular endothelial cells (PMVECs) by inhibiting the MAPKs/NF-κB pathways. Primary cultured rat PMVECs were transduced with lentiviral-borne Ace2 or shRNA-Ace2, and then treated or not with Mas receptor blocker (A779) before exposure to LPS. LPS stimulation resulted in the higher levels of AngII, Ang-(1-7), cytokine secretion, and apoptosis rates, and the lower ACE2/ACE ratio. Ace2 reversed the ACE2/ACE imbalance and increased Ang-(1-7) levels, thus reducing LPS-induced apoptosis and inflammation, while inhibition of Ace2 reversed all these effects. A779 abolished these protective effects of Ace2. LPS treatment was associated with activation of the ERK, p38, JNK, and NF-κB pathways, which were aggravated by A779. Pretreatment with A779 prevented the Ace2-induced blockade of p38, JNK, and NF-κB phosphorylation. However, only JNK inhibitor markedly reduced apoptosis and cytokine secretion in PMVECs with Ace2 deletion and A779 pretreatment. These results suggest that the ACE2/Ang-(1-7)/Mas axis has a crucial role in preventing LPS-induced apoptosis and inflammation of PMVECs, by inhibiting the JNK/NF-κB pathways.

Citing Articles

Sivelestat protects against acute lung injury by up-regulating angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptors.

He C, Li R, Zhang J, Chai W J Thorac Dis. 2024; 16(9):6182-6195.

PMID: 39444885 PMC: 11494560. DOI: 10.21037/jtd-24-1281.


Effects of Chronic Inflammatory Activation of Murine and Human Arterial Endothelial Cells at Normal Lipoprotein and Cholesterol Levels and .

Mussbacher M, Basilio J, Belakova B, Pirabe A, Ableitner E, Campos-Medina M Cells. 2024; 13(9.

PMID: 38727309 PMC: 11083315. DOI: 10.3390/cells13090773.


Exploring post-SEPSIS and post-COVID-19 syndromes: crossovers from pathophysiology to therapeutic approach.

Holmes D, Colaneri M, Palomba E, Gori A Front Med (Lausanne). 2024; 10:1280951.

PMID: 38249978 PMC: 10797045. DOI: 10.3389/fmed.2023.1280951.


ACE2 Expressed on Myeloid Cells Alleviates Sepsis-Induced Acute Liver Injury via the Ang-(1-7)-Mas Receptor Axis.

Liu L, Li Y, Li J, Xiao X, Wan T, Li H Inflammation. 2024; 47(3):891-908.

PMID: 38240986 DOI: 10.1007/s10753-023-01949-5.


Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin-Deficient Mice via Upregulation of Angiotensin (1-7).

Karasaki K, Kokubo H, Bumdelger B, Kaji N, Sakai C, Ishida M J Am Heart Assoc. 2023; 12(3):e027589.

PMID: 36718875 PMC: 9973615. DOI: 10.1161/JAHA.122.027589.


References
1.
Liu S, Feng G, Wang G, Liu G . p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Eur J Pharmacol. 2008; 584(1):159-65. DOI: 10.1016/j.ejphar.2008.02.009. View

2.
Kagan J, Medzhitov R . Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell. 2006; 125(5):943-55. DOI: 10.1016/j.cell.2006.03.047. View

3.
Gallagher P, Ferrario C, Tallant E . MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol. 2008; 295(5):C1169-74. PMC: 2585001. DOI: 10.1152/ajpcell.00145.2008. View

4.
Phua J, Badia J, Adhikari N, Friedrich J, Fowler R, Singh J . Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med. 2008; 179(3):220-7. DOI: 10.1164/rccm.200805-722OC. View

5.
Schuh K, Pahl A . Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury. Biochem Pharmacol. 2009; 77(12):1827-34. DOI: 10.1016/j.bcp.2009.03.012. View